SCHEDULE: Barclays Discloses 1.95% Stake in Ironwood Pharma

Barclays PLC has reported a 1.95% beneficial ownership stake in Ironwood Pharmaceuticals Inc., holding 3,167,713 common shares.

Summary

• Barclays PLC, a UK-based entity, reported beneficial ownership of 3,167,713 shares of Ironwood Pharmaceuticals Inc. common stock.
• This represents 1.95% of the class of securities.
• Barclays PLC holds sole voting power and sole dispositive power over all 3,167,713 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Ironwood Pharmaceuticals Inc.
• The filing identifies Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd as relevant subsidiaries.

Sentiment

Score: 5

Explanation: This is a factual beneficial ownership report (Schedule 13G) indicating a passive investment below the 5% threshold, thus it carries a neutral sentiment regarding the issuer's performance or outlook.

Future Outlook

NA

Management Comments

• Barclays PLC certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a 1.95% passive stake by a major financial institution like Barclays PLC may offer a minor signal of institutional interest, but is unlikely to significantly impact shareholder sentiment or company strategy due to its passive nature and size below the 5% threshold.

Key Dates

Keywords

Barclays PLC, Ironwood Pharmaceuticals Inc., Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake